Navigation Links
Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements
Date:2/16/2010

CRANBURY, N.J., Feb. 16 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced financial results for the fourth quarter and full year 2009.  The Company also provided an update on advancements in its product pipeline related to its key strategic priorities for 2010.  Additionally, the Company stated that it believes it is well positioned to achieve its key milestone of completing enrollment for its Phase 3 study of Amigal (migalastat HCl) to support approval in the U.S. (Study 011) by year end.

Fourth Quarter and Full-Year 2009 Financials Summary

Amicus announced net income attributable to common stockholders of $1.45 per share for the three months ended December 31, 2009. For the year ended December 31, 2009, the net loss attributable to common stockholders was $0.29 per share. As of December 31, 2009, cash, cash equivalents, and marketable securities totaled $78.2 million.

John F. Crowley, Chairman and CEO of Amicus Therapeutics stated, "We are very pleased with the significant progress we made advancing Amigal into Phase 3 in 2009, and we expect to continue this momentum in 2010.  We are confident in the likelihood of success for Amigal and are excited we have the potential to bring to market the first oral treatment to patients with Fabry disease."  

Key Strategic Priorities

The Company reaffirmed its three key strategic priorities for 2010: Phase 3 development of migalastat HCl for Fabry disease, advancing chaperone-ERT combina
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , 7 de julio de 2015 /PRNewswire/ ... de propiedad privada centrada en el desarrollo de ... neurovascular, ha anunciado hoy que R. Michael ... directiva. Kleine cuenta con más ... de los dispositivos médicos y la sanidad. Ha ...
(Date:7/7/2015)... , July 7, 2015 According ... by Method (Manual, Automated), Product (Consumables, Instrument), Application (Aerobic, Anaerobic, ... Academic Research Institute) - Forecast to 2019", published by MarketsandMarkets, ... $3,893.5 Million by 2019 from $2,750.2 Million in 2014 at ... 1 78 ma rket ...
(Date:7/7/2015)... Md. , July 7, 2015 ... (CRO) focusing in Oncology, Vaccines, and General Medicine ... the final locked database to Heron Therapeutics, Inc. ... 3 receptor antagonist product candidate SUSTOL® (granisetron ... regimen with the IV NK 1 receptor ...
Breaking Medicine Technology:Sequent Medical nombra a Mike Kleine a su junta directiva 2Sequent Medical nombra a Mike Kleine a su junta directiva 3Blood Culture Tests Market Worth $3,893.5 Million by 2019 2Blood Culture Tests Market Worth $3,893.5 Million by 2019 3Blood Culture Tests Market Worth $3,893.5 Million by 2019 4Accelovance Completes Trial Enrollment and Delivery of Clinical Data for Heron Therapeutics' Phase 3 Trial 2
... Supreme Court decision in Pliva v. Mensing is ... legal immunity when they ignore harmful side-effects of the drugs ... for generic manufacturers to ensure their drug is safe and ... This decision also means that brand-name manufacturers will be held ...
... Ill., June 23, 2011 Akorn, Inc. (NASDAQ: ... Tuesday, August 2, 2011, to discuss second quarter 2011 ... the same day before the market opens. Subject: , ... 2, 2011, at 10:00 a.m. Eastern TimeDomestic Callers: , ...
Cached Medicine Technology:Generic Drug Decision Disastrous to Patient Safety 2
(Date:7/7/2015)... ... July 07, 2015 , ... Dr. Poneh Ghasri , cosmetic dentist ... professional teeth whitening is one of the fastest, easiest ways to brighten a smile. ... decrease smile satisfaction and confidence. With the right teeth whitening treatment, patients can restore ...
(Date:7/7/2015)... ... July 07, 2015 , ... America is blessed with people who continually ... Hero program offers a special way to say “thanks.” Give them the recognition ... gift card and their place on the “Wall of Heroes.” , “We hear ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... ... executive Ellen Purdy as the company’s new Chief Financial Officer, effective July 6th, ... leadership experience in companies ranging from a multi-billion dollar, global chemical company to ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... with strong managerial expertise to oversee large healthcare operations and their success ... business partners, insurance companies, and regulators. American Sentinel University, an innovative, accredited ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... provider of unified communication management solutions, has announced the release of Service ... This service pack includes a number of enhancements to the already robust ...
Breaking Medicine News(10 mins):Health News:Los Angeles Cosmetic Dentist, Poneh Ghasri DDS, Now Offers Promotions on Whitening Treatments 2Health News:Los Angeles Cosmetic Dentist, Poneh Ghasri DDS, Now Offers Promotions on Whitening Treatments 3Health News:California Casualty Wants to Know: "Who Is Your Hero?" 2Health News:Office Practicum Announces new CFO 2Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 2Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 3Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 4Health News:ISI Telemanagement Solutions, Inc. Releases Service Pack 5600 for Infortel® Select 2
... ARBOR, Mich., Nov. 5 University of,Michigan executive ... passage of Proposal 2, the amendment to the ... to be derived from,embryos that have been created ... amendment would otherwise be discarded, unless,donated with informed ...
... study finds , , TUESDAY, Nov. 4 (HealthDay News) -- ... can raise the long term risk of death for ... , Surviving a heart attack or cardiac arrest ... later develop PTSD, which includes intense anxiety, flashbacks and ...
... - Conference Call Today at 9:00 a.m. EST -, ... MNKD ) today reported financial results for the third ... of 2008, total operating expenses were $69.1,million, compared to ... to the $9.2 million reduction in research and development,(R&D) ...
... Outpatient Services Are a Leading Factor for,Consolidation, ... NASHVILLE, Tenn., Nov. 5 HealthLeaders-InterStudy, a,leading ... that health,system expansion efforts in the Charleston, ... among local physician groups. According to the ...
... symptoms in half for passengers taking 7- to ... ... in the,journal of Minerva Cardioangiologica reveals Pycnogenol(R), pine bark,extract from the French ... study, consisting of a brain CT scan and a,scoring system, showed Pycnogenol(R) ...
... 5 BD (Becton,Dickinson and Company) (NYSE: BDX ... fourth fiscal quarter ended September 30, 2008,representing an increase ... growth rate reflects the favorable impact on all segments ... for 5,percentage points of the increase in quarterly revenues., ...
Cached Medicine News:Health News:The University of Michigan Welcomes Passage of Proposal 2 2Health News:The University of Michigan Welcomes Passage of Proposal 2 3Health News:The University of Michigan Welcomes Passage of Proposal 2 4Health News:Anxiety Linked to Heart Attack Can Raise Death Risk 2Health News:MannKind Corporation Reports Third Quarter Financial Results 2Health News:MannKind Corporation Reports Third Quarter Financial Results 3Health News:MannKind Corporation Reports Third Quarter Financial Results 4Health News:MannKind Corporation Reports Third Quarter Financial Results 5Health News:MannKind Corporation Reports Third Quarter Financial Results 6Health News:MannKind Corporation Reports Third Quarter Financial Results 7Health News:MannKind Corporation Reports Third Quarter Financial Results 8Health News:Charleston, S.C., Market Integration Likely to Drive Physician Groups to Seek Health System Affiliation 2Health News:Charleston, S.C., Market Integration Likely to Drive Physician Groups to Seek Health System Affiliation 3Health News:Study Shows Pine Bark Reduces Jetlag 2Health News:Study Shows Pine Bark Reduces Jetlag 3Health News:Study Shows Pine Bark Reduces Jetlag 4Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 2Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 3Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 4Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 5Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 6Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 7Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 8Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 9Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 10Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 11Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 12Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 13Health News:BD Announces Results for Fourth Fiscal Quarter and Full Year 14
... immunofluorescent antibody (IFA) test ... semi-quantitation of human serum ... viral capsid antigen (VCA). ... 12-well slides, FITC IgG ...
CMF OL1000 Bone Growth Stimulators are portable, battery-powered medical devices indicated for use in the noninvasive treatment of an established nonunion fracture acquired secondary to trauma, exclu...
... bone growth stimulator for the treatment of ... bone growth stimulator is a useful adjunct ... is already planned or when patient compliance ... is totally surgically implanted, patients are assured ...
... Stryker is proud to ... resectoscopes on the market at ... ergonomic design incorporates a superior ... and intuitive locking mechanisms. The ...
Medicine Products: